BRCA2 and mesothelioma: HRD was associated with the enrichment of SCNAs involving DNA damage response regulator BRCA2. HRD in mesothelioma likely underpins the observed response to PARP inhibition22 currently being explored in a randomised phase II clinical trial in patients with relapsed mesothelioma (NERO trials.gov identifier NCT05455424).